Type I IFN Gene Delivery Suppresses Regulatory T Cells Within Tumors
Overview
Oncology
Pharmacology
Affiliations
Type I interferon (IFN) is a pleiotropic cytokine regulating the cancer cell death and immune response. IFN-α can, as we have also reported, effectively induce an antitumor immunity by the activation of tumor-specific T cells and maturation of dendritic cells in various animal models. Unknown, however, is how the type I IFN alters the immunotolerant microenvironment in the tumors. Here, we found that intratumoral IFN-α gene transfer significantly decreased the frequency of regulatory T cells (Tregs) per CD4(+) T cells in tumors. The concentration of a Treg-inhibitory cytokine, interleukin (IL)-6, was correlated with the IFN-α expression level in tumors, and intratumoral CD11c(+) cells produced IL-6 in response to IFN-α stimulation. To confirm the role of IL-6 in the suppression of Tregs in tumors, an anti-IL-6 receptor antibody was administered in IFN-α-treated mice. The antibody increased the frequency of Tregs in the tumors, and attenuated systemic tumor-specific immunity induced by IFN-α. Furthermore, the IFN-α-mediated IL-6 production increased the frequency of Th17 cells in the tumors, which may be one of the mechanisms for the reduction of Tregs. The study demonstrated that IFN-α gene delivery creates an environment strongly supporting the enhancement of antitumor immunity through the suppression of Tregs.
Yin Z, Zhang H, Zhang K, Yue J, Tang R, Wang Y BMC Cancer. 2025; 25(1):474.
PMID: 40087599 DOI: 10.1186/s12885-025-13801-0.
Chernosky N, Tamagno I, Polak K, Ricky Chan E, Yuan X, Jackson M Breast Cancer Res. 2024; 26(1):167.
PMID: 39593161 PMC: 11590466. DOI: 10.1186/s13058-024-01918-2.
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K Signal Transduct Target Ther. 2024; 9(1):176.
PMID: 39034318 PMC: 11275440. DOI: 10.1038/s41392-024-01868-3.
Defaye M, Bradaia A, Abdullah N, Agosti F, Iftinca M, Delanne-Cumenal M J Clin Invest. 2024; 134(9).
PMID: 38690737 PMC: 11060736. DOI: 10.1172/JCI176474.
Recent Advances of RNA mA Modifications in Cancer Immunoediting and Immunotherapy.
Ma S, Barr T, Yu J Cancer Treat Res. 2023; 190:49-94.
PMID: 38112999 DOI: 10.1007/978-3-031-45654-1_3.